Michail A. Belyavskyi

Array ( [id] => 17286265 [patent_doc_number] => 11202803 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-12-21 [patent_title] => Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy [patent_app_type] => utility [patent_app_number] => 17/326088 [patent_app_country] => US [patent_app_date] => 2021-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 138 [patent_figures_cnt] => 196 [patent_no_of_words] => 104334 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 296 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17326088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19232198 [patent_doc_number] => 20240189389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => DRUG WITH PROLONGED ANALGESIC ACTION [patent_app_type] => utility [patent_app_number] => 17/926318 [patent_app_country] => US [patent_app_date] => 2021-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8157 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926318 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19232198 [patent_doc_number] => 20240189389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => DRUG WITH PROLONGED ANALGESIC ACTION [patent_app_type] => utility [patent_app_number] => 17/926318 [patent_app_country] => US [patent_app_date] => 2021-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8157 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926318 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451535 [patent_doc_number] => 20230192813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => ANTIBODY THAT BINDS SPECIFICALLY TO THE SARS COV 2 SPIKE PROTEIN, AND METHODS FOR ITS MANUFACTURE [patent_app_type] => utility [patent_app_number] => 17/926359 [patent_app_country] => US [patent_app_date] => 2021-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451535 [patent_doc_number] => 20230192813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => ANTIBODY THAT BINDS SPECIFICALLY TO THE SARS COV 2 SPIKE PROTEIN, AND METHODS FOR ITS MANUFACTURE [patent_app_type] => utility [patent_app_number] => 17/926359 [patent_app_country] => US [patent_app_date] => 2021-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451535 [patent_doc_number] => 20230192813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => ANTIBODY THAT BINDS SPECIFICALLY TO THE SARS COV 2 SPIKE PROTEIN, AND METHODS FOR ITS MANUFACTURE [patent_app_type] => utility [patent_app_number] => 17/926359 [patent_app_country] => US [patent_app_date] => 2021-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18484929 [patent_doc_number] => 20230212243 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => Neoantigenic Epitopes Associated with SF3B1 Mutations [patent_app_type] => utility [patent_app_number] => 17/924013 [patent_app_country] => US [patent_app_date] => 2021-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35733 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17924013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18484929 [patent_doc_number] => 20230212243 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => Neoantigenic Epitopes Associated with SF3B1 Mutations [patent_app_type] => utility [patent_app_number] => 17/924013 [patent_app_country] => US [patent_app_date] => 2021-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35733 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17924013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420177 [patent_doc_number] => 20230174638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => FORMULATIONS OF ANTI-IL-33 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/998388 [patent_app_country] => US [patent_app_date] => 2021-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13621 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18739887 [patent_doc_number] => 20230348854 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => CHIMERIC ANTIGEN RECEPTORS (CARS) TARGETING NATURAL KILLER CELLS [patent_app_type] => utility [patent_app_number] => 17/998206 [patent_app_country] => US [patent_app_date] => 2021-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47842 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -110 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18434346 [patent_doc_number] => 20230181640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => ANTI-BCMA ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/924410 [patent_app_country] => US [patent_app_date] => 2021-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 253 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17924410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18739625 [patent_doc_number] => 20230348585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => METHODS FOR TREATING OR REDUCING THE SEVERITY OF A VIRAL INFECTION [patent_app_type] => utility [patent_app_number] => 17/923029 [patent_app_country] => US [patent_app_date] => 2021-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449619 [patent_doc_number] => 20230190895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => NEGATIVELY CHARGED PARTICLES FOR THE TREATMENT OF CYTOKINE STORM SYNDROME (CSS) AND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) [patent_app_type] => utility [patent_app_number] => 17/922484 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24259 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17922484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18418590 [patent_doc_number] => 20230173048 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => ANTI-CANCER VACCINES AND RELATED THERAPY [patent_app_type] => utility [patent_app_number] => 17/921837 [patent_app_country] => US [patent_app_date] => 2021-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17921837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18437476 [patent_doc_number] => 20230184771 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => METHODS FOR TREATING BLADDER CANCER [patent_app_type] => utility [patent_app_number] => 17/996828 [patent_app_country] => US [patent_app_date] => 2021-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22054 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -101 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451516 [patent_doc_number] => 20230192794 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => ENGINEERED INTERLEUKIN-22 POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/995985 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33505 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -80 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451516 [patent_doc_number] => 20230192794 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => ENGINEERED INTERLEUKIN-22 POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/995985 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33505 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -80 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497401 [patent_doc_number] => 20230220031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => ENGINEERED IL-12 AND IL-23 POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/995986 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -75 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497401 [patent_doc_number] => 20230220031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => ENGINEERED IL-12 AND IL-23 POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/995986 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -75 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18596024 [patent_doc_number] => 20230270815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => Apoptosis inducing peptide (SSTP1) [patent_app_type] => utility [patent_app_number] => 17/919130 [patent_app_country] => US [patent_app_date] => 2021-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4068 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17919130 [rel_patent_id] =>[rel_patent_doc_number] =>)